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Abstract: Messenger RNA encodes cellular function and phenotype. In the context of human 
cancer it defines the identity of malignant cells and diversity of tumor tissue. We studied 
72,501 single cell transcriptomes of human renal tumors and normal tissue from fetal, 5 
pediatric and adult kidneys. We matched childhood Wilms’ tumor with specific fetal cell 
types, thus providing evidence for the hypothesis that Wilms’ tumor cells are aberrant fetal 
cells. In adult renal cell carcinoma we identified a canonical cancer transcriptome that 
matched a little known subtype of proximal convoluted tubular cell. Analyses of the tumor 
composition identified cancer-associated normal cells and delineated a complex VEGF 10 
signaling circuit. Our findings reveal the precise cellular identity and composition of human 
kidney tumors. 
 
One Sentence Summary: Single cell mRNAs of 72,501 normal and cancerous kidney cells 
reveals the cellular identity of childhood and adult tumors.  15 
 
Main Text: Cancer cell identity is defined by morphological appearance, tissue context, and 
marker gene expression. Single cell transcriptomics refines the cellular identity on the basis of a 
comprehensive and quantitative read out of messenger RNA.  Precise cellular transcriptomes may 
reveal a tumor’s cell of origin and the transcriptional trajectories underpinning malignant 20 
transformation (1). 
 
We sought to define the identity of normal and cancerous human kidney cells from a catalogue of 
72,501 single kidney cell transcriptomes, integrated with tumor whole genome DNA sequences 
(2). We studied Wilms’ tumor, clear cell papillary (pRCC) and clear cell renal cell carcinoma 25 
(ccRCC) in relation to healthy fetal (n=2), pediatric (n=3), adolescent (n=2), and adult kidneys 
(n=5), as well as ureters (n=4; Table S1)  
 
Normal tissue biopsies were taken from macroscopically normal regions of kidneys resected due 
to cancer (n=10) or for transplantation (n=2). We performed technical replicates of each biopsy 30 
and biological replicates, where clinically permissible (Table S1). We processed kidneys 
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immediately following resection, generating single cell solutions enriched for viable cells. We 
derived counts of mRNA molecules in each cell for further analyses, subject to quality control (2).  
 
We split 72,501 fetal, normal, and tumor cells into immune and non-immune compartments (Fig. 
S1).  Using a community detection algorithm (2), transcriptomes were further segregated into 5 
distinct clusters of cells (Table S2).  We first generated a reference map of normal mature and 
fetal cells, assigning an identity to each cluster, by cross-referencing cluster-defining transcripts 
with canonical markers curated from the literature (Table S3). Ambiguous clusters were not 
included in the reference map and are presented in Fig. S2-S8. Highly specific cluster-defining 
transcripts, which are potential cell markers, are appended as a resource (Table S4).  10 
 
Amongst 42,809 non-malignant cells, 37,951 mature kidney cells segregated into epithelial cells 
representing the distinct micro-anatomical regions of the nephron, particularly a large proportion 
of proximal tubular cells (Fig. 1A-C, Fig. S4). Furthermore, there were fibroblasts, 
myofibroblasts, and vascular endothelial cells, i.e. glomerular endothelium, ascending and 15 
descending vasa recta (Fig. 1D, Fig. S2). 4,858 fetal cells grouped into developing nephron cells 
(ureteric bud, cap mesenchyme,  primitive vesicle) and fibroblasts, myofibroblasts, vascular 
endothelial and ganglion cells (Fig. 2A-C, Fig. S5).  
 
To determine transcriptional programs underlying nephron development, we identified 20 
differentially expressed transcription factors in ureteric bud cells against cap mesenchyme and 
primitive vesicle cells (Fig. 2D). Furthermore, we applied pseudo-timing methods to identify 
transcription factors that define the transition from cap mesenchyme to primitive vesicle (Fig. 2D). 
Together, these analyses identified established, and unknown, transcription factors associated with 
nephron development as a reference for subsequent analyses of malignant processes (Table S5).  25 
 
Having established the single cell landscape of healthy kidneys, we characterized the cellular 
identity of 6,333 non-immune (Fig. S7) and 17,821 immune (Fig. S8) tumor cells.  We analyzed 
three types of tumors (Table S1): Wilms’ (n=3); ccRCC (n=3) pRCC (n=1). Children had received 
neoadjuvant cytotoxic treatment prior to nephrectomy, as per British practice. Although this pre-30 
treatment reduced yield (Table S6), recovered cells represent the therapeutically relevant 
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surviving cancer cells that determine the degree of adjuvant cytotoxic chemotherapy required (3). 
We used logistic regression to quantify the similarity between tumor cell clusters and normal cells, 
validated through intrinsic control populations (2). That is, the model found myofibroblasts from 
tumors matched myofibroblasts from mature and fetal kidneys (Fig. 3A) and no match for a 
negative control population, mast cells, inserted into the training data. 5 
 
This similarity metric may be obfuscated by the phenotypic plasticity of tumor cells. We developed 
a method to genotype individual cancer cells from mRNA reads from somatic copy number 
changes (Table S7; Fig. S9) as defined by tumor whole genome sequences (Fig. S10). We 
validated genotyping calls by leveraging phasing of single nucleotide polymorphisms across 10 
segments with altered copy number, by testing for the presence of somatic single nucleotide 
variants, and by comparison to control populations (Fig. S11-S14).  
 
Integrating genotyping and similarity analyses, we found that Wilms’ cells resembled fetal normal 
cells, evidencing that Wilms’ tumor represents aberrant fetal cells. We found different populations 15 
of Wilms’ tumor that matched specific populations of the developing nephron (Fig. 3A), 
representing ureteric-bud and primitive vesicle cells. One cluster (WF), composed of Wilms’ 
cancer cells and non-cancerous ccRCC fibroblasts, exhibited a fibroblast-myofibroblast 
transcriptome. In one case, we obtained an anatomically separate perilobar nephrogenic rest, 
thought to represent a precursor lesion of Wilms’. Like Wilms’ cancer cells, we observed that 20 
nephrogenic rest resembled ureteric bud or primitive vesicle. This suggests that the potential to 
generate the different cell states of the fetal nephron is acquired early, or was not lost, by the 
developing Wilms’ cancer, although this conclusion is based on only one sample.  
 
To validate the cellular identity of Wilms’ cells, we interrogated bulk transcriptomes of an 25 
independent series of 124 Wilms’ tumors for cellular signatures of ureteric bud and primitive 
vesicle (4, 5). We extracted specific markers expressed within ureteric bud or primitive vesicle 
and nowhere else amongst non-tumor single cells (Table S8, (2)), and probed bulk transcriptomes 
for these cluster defining transcripts. As comparators to Wilms’ we included fetal, pediatric, and 
adult normal tissue bulk transcriptomes (n=135) and other childhood kidney tumors (17 congenital 30 
mesoblastic nephroma, 65 malignant rhabdoid tumor). Consistent with our findings, signatures of 
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primitive vesicle and ureteric bud cells were seen in, and confined to, Wilms’ and normal fetal 
tissue, thus corroborating the presence of these cells in Wilms’ tumor (Fig. 3B).  
 
Placing Wilms’ tumor cells in pseudo-time revealed two transcriptional programs emanating from 
the ureteric bud: one branch predominantly describing the development of nephrogenic rest cells 5 
and the other of Wilms’ cancer cells (Fig. 3C). There was a significant overlap in the transcription 
factors underpinning these two programs (Fig 3D; Table S9) and normal nephrogenesis (p<10-4; 
hypergeometric test). This indicates that developmental relationships exist between Wilms’ tumor 
cells that have been adopted from normal nephrogenesis. Our analyses of Wilms’ cells reveal their 
plasticity, fetal identity and define the transcriptional readout of developmental cell states and 10 
trajectories that may harbor targetable vulnerabilities. 
 
Next we studied ccRCC and pRCC (type 1), including one case of von Hippel Lindau disease-
related ccRCC (Table S1). Matching ccRCC and pRCC with normal mature cells, we found that 
they retained transcriptional features of cluster PT1, a specific subtype of convoluted proximal 15 
tubular cell (Fig. 4A). Most (6/7) ccRCC clusters and all pRCC cells matched this particular PT1 
cell, indicating that it represents an RCC cell state that transcends the diversity of RCC cells within 
and across tumors.  Little is known about the nearest normal cell correlate of RCC, the PT1 cell, 
which has been identified to become more abundant in inflamed renal tissue (6).  
 20 
To validate the identity of the PT1 signature in RCC, we exploited the fact that they were defined 
by specific markers within our data, SLC17A3 and VCAM1 with absence of SLC7A13 (Fig. 4B; 
Fig. S2). We measured these transcripts in an independent series of 1,019 publicly available bulk 
kidney tumor and normal tissue transcriptomes. High expression of SLC17A3 mRNA 
distinguished ccRCC and pRCC, type 1 and 2, from chromophobe RCC (p<10-4; Mann-Whitney 25 
test), whereas SLC7A13 mRNA was significantly depleted in ccRCC/pRCC bulk transcriptomes 
versus normal (p<10-4; Mann-Whitney test), as were mRNAs representing other regions of the 
nephron (Fig. 4B). VCAM1 transcripts, a specific PT1 marker within proximal tubules, was also 
significantly elevated across RCC bulk transcriptomes (p<10-4; Mann-Whitney test; Fig. 4B), with 
each individual RCC tumor exhibiting the PT1 signature (Fig. S15). Confocal microscopy 30 
demonstrated co-localization of VCAM1 and SLC17A3 in CA9+ cells, CA9 being a specific 
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marker of ccRCC cells (Fig. 4C). Furthermore, we investigated VCAM1 expression in the earliest 
precursor lesions of ccRCC: CA9+ proximal tubular cells residing within morphologically normal 
kidney tissue predisposed to ccRCC through pathogenic germline mutation of VHL. Examining 
tissue from three individuals, we identified CA9+/VCAM1+ clusters of proximal tubular cells 
(Fig. 4D). Similarly, tumors arising in these kidneys harbored CA9+/VCAM1+ cells (Fig. S16). 5 
As expected, VCAM1 was otherwise sparsely expressed on proximal tubular cells. Together these 
observations substantiate our proposition that PT1 cells are the nearest normal cell correlate of 
ccRCC cells. The presence of the PT1 signature in both ccRCC and pRCC may indicate a common 
origin of these tumors with divergent fates.   
 10 
Apart from the PT1 signature in pRCC and ccRCC, we found that one ccRCC cell cluster (cR7) 
matched PT3 cells and that pRCC cells exhibited an additional, weaker match with collecting duct 
cells (Fig. 4A). Neither signal was enriched in bulk transcriptomes (Fig. 4B). As our study was 
confined to a single type 1 pRCC, it is possible that we missed additional pRCC cell types. 
 15 
Finally, we dissected the tumor microenvironment occupied by cancer-associated normal cells, 
comprised of immune cells, fibroblasts, myofibroblasts and vascular endothelial cells, 
predominately ascending vasa recta cells (Fig. S7, S8, S17). Within these we studied VEGF 
signaling, an established target of RCC treatment (7, 8). The VEGF signaling circuit in renal 
tumors involves VEGFA secretion from RCC cells resulting in a response from endothelial cells 20 
(7, 8). Measuring expression of the key components of VEGF signaling, we identified tumor 
infiltrating macrophages as a further source of VEGFA mRNA(Fig. S18A), confirmed by confocal 
microscopy of ccRCC cells and flow cytometry of an independent ccRCC tumor (Fig. S18B,C,D). 
VEGF-signaling receptors (KDR, FLT1, FLT4) were mainly expressed by one population of 
ascending vasa recta cells (Fig. S18A, cluster tE1). The other ascending vasa recta cluster, tE2, 25 
(Fig. S18A) exhibited lymphangiogenic VEGFC mRNA and FLT1. tE2 endothelial cells 
expressed high levels of ACKR1, a marker of venular endothelium promoting tissue migration of 
immune cells into tissue (9). Overall these findings delineate a complex VEGF signaling circuit 




By identifying specific normal cell correlates of renal cancer cells, our study moves our 
understanding of these malignancies beyond a notion of “fetalness” or an approximate micro-
anatomical region to a precise cellular, molecularly quantitative resolution. Our findings portray 
the age predilection of Wilms’ tumor to early childhood as a continuum of fetal nephrogenesis, in 
contrast to the life-long risk for RCC development. Our study provides a scalable experimental 5 
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Figure 1. Canonical cell types in normal human kidneys. 
(A) Illustration of nephron anatomy with single cell clusters marked. 
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(B) tSNE representation of 8,707 normal epithelial and vascular cells. Clusters are colored, 
uniquely labelled and emphasized with density contours.  Ambiguous clusters are de-emphasized 
and fully shown in Fig. S2. 
(C) Expression of canonical nephron markers (Table S3) in clusters from (A).  Colors give the 
fraction of cells expressing each gene in a cluster, scaled to have mean 0 and standard deviation 5 
1 across all clusters. 









Figure 2. Fetal cell types and nephrogenesis. 
(A) tSNE representation of 4,858 fetal epithelial and vascular cells, colored and labelled as in 
Fig. 1A.  
(B) Expression of gene markers of clusters in (A), colored as in Fig. 1C. 5 
(C) Expression of markers of nephron development in clusters from (A) with illustration of 
nephron development. Formation of nephrons emanates from the ureteric bud, which induces 
condensation of the overlying mesenchyme into the cap mesenchyme. Cells from cap 
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mesenchyme then form the primitive vesicle, the precursor of the glomerulus. The tubular 
system grows out from both ends of the fetal nephron: ureteric bud and primitive vesicle.   
(D) The expression of transcription factor which vary significantly (p<0.01) along the pseudo-
time trajectory defined using the CM and PV cells from (C), or differentially expressed between 
UB versus CM and PV. UB expression is shown in a separated block on the left. Within the right 5 
block, pseudo-time increases from left to right and rows are clustered and grouped by 
hierarchical clustering with canonical transcription factors of nephrogenesis highlighted (see 
Table S6). 
 




Figure 3. Matching childhood tumors with normal fetal cells. 
(A) Similarity of Wilms’ tumor and cancer-associated normal cells to the reference fetal kidney 
map (Fig. 2A), with mast cells added as a negative control population. Square boxes indicate 
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sample contribution. Colors represent the probability that the cluster identified in the column 
header is "similar" to the fetal cluster identified by the row label (2). 
(B) Expression of canonical tumor markers and representative UB and PV specific genes (Table 
S8) in RNA-seq from childhood cancers (yellow), normal tissue (blue) or adult cancers (green). 
MRT: malignant rhabdoid tumor; CMN: congenital mesoblastic nephroma. As positive controls, 5 
canonical tumor markers are shown: WT1 (Wilms’); CA9 (ccRCC).  
(C) Pseudo-time trajectory of all Wilms tumor and nephrogenic rest cell.  Square boxes indicate 
sample contribution.  The color shows the similarity score of each cell to the PV or UB foetal 
population.  Jitter has been added to each point’s position with the points original position 
plotted underneath in black (2). 10 
(D) Transcription factors identified as varying significantly along the pseudo-time trajectory in 
(C). The center of the heatmap corresponds to the cells at the top of (C) and then proceeding 






Figure 4. Matching adult tumors with normal mature kidney cells. 
(A) Similarity of adult cancer and cancer-associated normal cells to mature kidney reference map 
(Fig. 1B), with mast cells added as a negative control population. Square boxes indicate sample 
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contribution. Colors represent the probability that the cluster identified in the column header is 
"similar" to the normal cluster identified by the row label (2). 
(B) Expression of nephron specific genes in bulk RNA-seq as in Fig. 3B. pRCC samples are both 
type 1 and 2. 
(C) Confocal microscopy showing co-localization of PT1 markers (VCAM1, SLC17A3) in 5 
ccRCC cells (CA9). 
(D) Staining of a proximal tubular ccRCC precursor lesion (CA9) for the PT1 marker, VCAM1.  
